Rajesh V. Lalla, DDS, PhD
COMMENTING ON the results of this trial of GC4419, Rajesh V. Lalla, DDS, PhD, President of the Multinational Association of Supportive Care in Cancer, said, “This study demonstrated this agent’s strong potential for the management of oral mucositis in patients receiving head and neck radiation therapy.”
“The findings are not yet ready to be translated to practice, because this agent is not approved for this indication by the U.S. Food and Drug Administration [FDA],” he told The ASCO Post. “But a phase III clinical trial is currently being planned, and we eagerly look forward to the results of that trial. Hopefully, positive results will allow this agent to be approved by the FDA and applied into practice.” ■
DISCLOSURE: Dr. Lalla is a consultant for and has received research support from Galera Therapeutics, the sponsor of the trial discussed here.
Carryn Anderson, MD
GC4419, A SMALL molecule superoxide dismutase mimetic, reduced the duration, incidence, and severity of chemoradiotherapy-induced mucositis in patients with locally advanced head and neck cancer, with a safety profile comparable to that of placebo. This finding comes from...